Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Phase 1

A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

NCT07897721 · tracked via the Priya Life Science USA tracker
Sponsor
Phase
Phase 1
Started
2026-11-09
Last updated
2026-11-18

Condition(s) studied

Advanced Breast CancerAdvanced or Metastatic Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Metastatic Colorectal Adenocarcinoma

Investigational drug(s) / intervention(s)

PF-08165784Fulvestrant →Atirmociclib →Cetuximab →Letrozole →

PF-08165784: Taken by mouth (PO)

Fulvestrant: Selective Estrogen Receptor Degrader (SERD)

Atirmociclib: Selective CDK4 inhibitor

Cetuximab: Monoclonal antibody (EGFR inhibitor)

Letrozole: Nonsteroidal aromatase inhibitor

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.

This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.

All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years of age or older * Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease * PIK3CA mutation * Archived tumor specimen or fresh tumor biopsy * Measurable disease * ECOG performance status 0 or 1 Exclusion Criteria: * Active or clinically significant dermatologic conditions * Active malignancy within 3 years prior to enrollment * Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term * Major surgery or radiation therapy within 3 weeks prior to study entry * Prior irradiation to \>25% of the bone marrow * Active or history of pneumonitis/interstitial lung disease requiring corticosteroids * Unmanageable ascites * Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol. * Renal impairment * Hepatic dysfunction * Hematologic abnormalities * Uncontrolled diabetes * Cardiac abnormalities * Active or history of clinically significant GI or inflammatory GI disease * Other unacceptable abnormalities or prohibited therapies as defined by protocol

Primary outcome measure(s)

  • Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT) — Baseline up to 28 days
    Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.
  • Part 1 (Dose Escalation): Incidence of Adverse Events (AEs) — From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
    An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.
  • Part 1 (Dose Escalation): Number of participants with laboratory abnormalities — From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
    Number of participants with laboratory test abnormalities.
  • Part 2 (Dose Expansion): Objective Response Rate (ORR) — Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
    ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Trial sites (5)

FacilityCityRegionStatus
Highlands Oncology Group, PA Fayetteville Arkansas
Highlands Oncology Group, PA Rogers Arkansas
Highlands Oncology Group, PA Springdale Arkansas
START Midwest, LLC Grand Rapids Michigan
Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office San Juan Puerto Rico
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07897721 on ClinicalTrials.gov ↗ ← All trials in the USA